Nephrology Drugs Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Nephrology Drugs Market Size Analysis and Top Companies

The global nephrology drug market size is estimated at to hit around USD 28.72 billion by 2033 from USD 17.71 billion in 2024 with a CAGR of 5.52% from 2024 tpo 2033. The top companies operating in the nephrology drugs market are AstraZeneca, AbbVie Inc., Akebia Therapeutics, Inc., Amgen Inc., F. Hoffmann-La Roche, FibroGen Inc., Johnson & Johnson Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG and Others.

Market Scope

Nephrology Drugs Market Companies

• AstraZeneca
• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Amgen Inc.
• F. Hoffmann-La Roche
• FibroGen Inc.
• Johnson & Johnson Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Limited
• Reata Pharmaceuticals, Inc.
• GlaxoSmithKline plc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG

Recent Developments

• Grupo Olmos, a firm that offers renal care solutions, said in July 2022 that it had purchased the renal care division of Diaverum, an Argentinean supplier of renal healthcare. The company's renal product portfolio will be strengthened by the purchase of the renal business.
• The biggest private healthcare organization with operations throughout many GCC states, Aster Hospitals, said in March 2019 that it has begun a screening and awareness campaign to encourage the early detection and prevention of chronic kidney disease (CKD).

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344